Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
基本信息
- 批准号:6797384
- 负责人:
- 金额:$ 99.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-26 至 2006-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Cellulose acetate phthalate (CAP) has
been used as an enteric film coating material or as a matrix binder for
tablets and capsules. It is widely used in oral pharmaceutical products and
is generally regarded as a nontoxic material free of adverse effects. It is
included in the FDA Inactive Ingredients Guide and is listed in pharmacopoeias
internationally. CAP is available in large quantities and is inexpensive. It
was demonstrated that CAP: 1) has antiviral activity against HIV-1 and several
herpesviruses (HSV); and 2) when formulated in a micronized form a)
inactivated in vitro HIV-1, HSV-1. HSV-2, cytomegalovirus, Neisseria
gonorrhoeae, Trichomonas vaginalis, Haemophilus ducreyi and Chlamydia
trachomatis; b) inactivated bacteria associated with bacterial vaginosis; c)
protected mice against vaginal infection by HSV-2; and d) protected 4/6 rhesus
monkeys from vaginal infection with simian immunodeficiency virus (SIVmac251).
These results have established the promise of CAP as a microbicide for
prevention of sexual transmission of HIV-1. Additional preclinical studies are
needed to further support this promise. This includes: (Project I): Prevention
of infection by primary HIV-1 isolates and distinct HIV-1 clades in cell
cultures in vitro and in human cervical and rectal tissue models; (Project
II): a) Assess the safety of CAP in a monkey model by colposcopic examinations
and measurement of pro-inflammatory chemokines and cytokines; b) Assessment of
CAP distribution after vaginal application in monkeys using chemically tagged
CAP and colposcopy, and magnetic resonance imaging (MRI); and c) Evaluate the
efficacy of CAP against infection with pathogenic X4- and R5-specific
simian/human chimeric HIV viruses (SHIV), respectively; (Project III):
Measurement of pro-inflammatory chemokines and cytokines after exposure of
cervical and vaginal epithelial cells in culture to CAP; (Project IV): Studies
on CAP-human sperm interactions to assess the spermicidal/contraceptive
potential of CAP and its formulations. Information gained from the proposed
studies, coordinated and supplied by uniform and quality controlled
formulations by Cores A, B, respectively, is expected to facilitate the design
of Phase I, II and III human clinical trials. CAP meets criteria proposed for
an ideal microbicide: activity in presence of semen and blood; activity
against sexually transmitted infections other than HIV-1; condom
compatibility, negligible systemic absorption (due to its large, molecular
mass and micronized state); lack of color and unpleasant taste; and low cost.
The proposed research is expected to help transform this ideal into a reality.
描述(由申请人提供):邻苯二甲酸醋酸纤维素(CAP)具有
用作肠溶膜包衣材料或基质粘合剂
片剂和胶囊。广泛应用于口服药品和
通常被认为是无毒材料,没有不良影响。这是
包含在 FDA 非活性成分指南中并被列入药典
国际上。 CAP 大量供应且价格低廉。它
已证明 CAP:1) 对 HIV-1 和多种病毒具有抗病毒活性
疱疹病毒(HSV); 2) 当以微粉化形式配制时 a)
体外灭活HIV-1、HSV-1。 HSV-2、巨细胞病毒、奈瑟菌
淋病、阴道毛滴虫、杜克雷嗜血杆菌和衣原体
沙眼衣原体; b) 与细菌性阴道病相关的灭活细菌; c)
保护小鼠免受 HSV-2 阴道感染; d) 受保护的 4/6 恒河猴
猴子阴道感染猿猴免疫缺陷病毒(SIVmac251)。
这些结果证实了 CAP 作为杀微生物剂的前景
预防 HIV-1 的性传播。其他临床前研究是
需要进一步支持这一承诺。这包括:(项目一):预防
原代 HIV-1 分离株和细胞中不同 HIV-1 进化枝的感染率
体外培养以及人类宫颈和直肠组织模型中的培养; (项目
II): a) 通过阴道镜检查评估 CAP 在猴模型中的安全性
促炎趋化因子和细胞因子的测量; b) 评估
使用化学标记的猴子阴道施用后 CAP 分布
CAP 和阴道镜检查以及磁共振成像 (MRI); c) 评估
CAP 对致病性 X4 和 R5 特异性感染的功效
分别是猿猴/人类嵌合HIV病毒(SHIV); (项目三):
暴露后促炎趋化因子和细胞因子的测量
宫颈和阴道上皮细胞培养至 CAP; (项目四):研究
CAP 与人类精子相互作用以评估杀精/避孕效果
CAP 及其配方的潜力。从提议中获得的信息
由统一和质量控制协调和提供的研究
核心 A、B 的配方预计将有助于设计
I、II 和 III 期人体临床试验。 CAP 符合建议的标准
理想的杀菌剂:在精液和血液存在下具有活性;活动
预防 HIV-1 以外的性传播感染;避孕套
相容性,可忽略不计的全身吸收(由于其大分子
质量和微粉化状态);缺乏颜色和难闻的味道;且成本低。
拟议的研究预计将有助于将这一理想变为现实。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Guiding the vaginal microbicide trials with biomarkers of inflammation
- DOI:10.1097/00126334-200410013-00010
- 发表时间:2004-10-01
- 期刊:
- 影响因子:3.6
- 作者:Fichorova, RN
- 通讯作者:Fichorova, RN
Anti-HIV-1 activity of poly(mandelic acid) derivatives.
- DOI:10.1021/bm070221y
- 发表时间:2007-10
- 期刊:
- 影响因子:6.2
- 作者:Marty Ward;Bing Yu;V. Wyatt;Jelani Griffith;Tara L. Craft;A. Neurath;N. Strick;Yun-yao Li;D. Wertz;J. Pojman;A. Lowe
- 通讯作者:Marty Ward;Bing Yu;V. Wyatt;Jelani Griffith;Tara L. Craft;A. Neurath;N. Strick;Yun-yao Li;D. Wertz;J. Pojman;A. Lowe
Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques.
醋酸纤维素 1,2-苯二甲酸 (CAP) 的安全性和分布,它是一种候选抗 HIV 杀菌剂,在恒河猴中使用。
- DOI:10.1097/01.aids.0000185990.16477.47
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Ratterree,Marion;Gettie,Agegnehu;Williams,Victoria;Malenbaum,Susan;Neurath,ARobert;Cheng-Mayer,Cecilia;Blanchard,James
- 通讯作者:Blanchard,James
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A ROBERT ROBERT NEURATH其他文献
A ROBERT ROBERT NEURATH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A ROBERT ROBERT NEURATH', 18)}}的其他基金
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film
抗HIV-1复合醋酸纤维素邻苯二甲酸酯薄膜
- 批准号:
6803829 - 财政年份:2004
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film
抗HIV-1复合醋酸纤维素邻苯二甲酸酯薄膜
- 批准号:
6953768 - 财政年份:2004
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6608543 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6443010 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6526238 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2460748 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2292288 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2751045 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
相似海外基金
Effects of per- and polyfluoroalkyl substances on placental features and size at birth
全氟烷基和多氟烷基物质对出生时胎盘特征和大小的影响
- 批准号:
10645524 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
醋酸鲁沙来肽 (TP508) 对放射诱发的角膜病变的缓解作用
- 批准号:
10605739 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Gut microbiota metabolite sensing licenses IEC to cross talk with T cells to inhibit intestinal inflammation
肠道微生物代谢传感许可 IEC 与 T 细胞交互作用以抑制肠道炎症
- 批准号:
10602998 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10573109 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10818835 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Prenatal Cigarette Smoke Exposure: Impact on Offspring Gut Bacterial Microbiome
产前香烟烟雾暴露:对后代肠道细菌微生物组的影响
- 批准号:
10747173 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA
小肠微生物驱动内脏疼痛的机制
- 批准号:
10836298 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Evaluating the Mechanisms of Afferent Renal Nerve Ablation as a Treatment for Hypertension
评估传入肾神经消融治疗高血压的机制
- 批准号:
10604700 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:














{{item.name}}会员




